NCM · Financial Statements

Allarity Therapeutics, Inc. (ALLR) Financial Statements

$0.87 NCM: ALLR Market Cap $13.77M

Allarity Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $11.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Allarity Therapeutics, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -3132.1% to -3939.1%, a shift of -806.9 percentage points; the most recent year shows a net loss of $11.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$1.0M$1.0M$0$0$0$0$0$0$0
Operating Expenses$5.0M$5.0M$6.0M$18.0M$8.0M$27.0M$34.0M$17.0M$27.0M$13.0M
Operating Profit$-4.0M$-4.0M$-5.0M$-18.0M$-8.0M$-27.0M$-34.0M$-17.0M$-27.0M$-13.0M
Operating Margin-3132.1%-263.4%-341.2%-14675.8%0.0%0.0%0.0%0.0%0.0%-3939.1%
Other Income$0$-1.0M$2.0M$-1.0M$2.0M$0$17.0M$5.0M$2.0M$1.0M
Interest$0$0$0$3.0M$0$1.0M$0$0$1.0M$0
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-4.0M$-5.0M$-3.0M$-19.0M$-6.0M$-27.0M$-18.0M$-12.0M$-25.0M$-11.0M
Tax$17.2M$1.9M$31.0M$24.1M$-3.1M$-500,000$8.7M$-700,000$1.5M$0
Net Profit$-4.0M$-5.0M$-2.0M$-14.0M$-7.0M$-27.0M$-16.0M$-12.0M$-25.0M$-11.0M
EPS$0.00$0.00$0.00$-189613.00$-1698639.00$-79074.18$-31799.09$-6031.31$-15.79$-0.78
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$4.0M$5.0M$4.0M$3.0M$12.0M$7.0M$3.0M$4.0M$3.0M$3.0M$3.0M$3.0M
Operating Profit$-4.0M$-5.0M$-4.0M$-3.0M$-12.0M$-7.0M$-3.0M$-4.0M$-3.0M$-3.0M$-3.0M$-3.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%-911.9%-10752.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$1.0M
Profit Before Tax$-4.0M$-2.0M$-4.0M$-2.0M$-12.0M$-7.0M$-3.0M$-2.0M$-3.0M$-3.0M$-3.0M$-3.0M
Tax$0$-5.1M$100,000$0$3.1M$0$0$0$0$0$0$0
Net Profit$-4.0M$-2.0M$-4.0M$-2.0M$-12.0M$-7.0M$-3.0M$-2.0M$-3.0M$-3.0M$-3.0M$-3.0M
EPS$-1346.09$-175.51$-20905.00$-3.40$-7.71$-1.02$-0.25$-0.15$-0.19$-0.21$-0.17$-0.21

Over the 10 years reported for Allarity Therapeutics, Inc., cash stood at $15.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.25 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$7.0M$2.0M$39.0M$32.0M$33.0M$50.0M$15.0M$12.0M$23.0M$18.0M
Current Assets$4.0M$1.0M$2.0M$3.0M$2.0M$21.0M$5.0M$2.0M$22.0M$18.0M
Cash$2.0M$1.0M$0$2.0M$0$20.0M$2.0M$0$20.0M$15.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$2.0M$1.0M$1.0M$1.0M$1.0M$2.0M$1.0M
Fixed Assets$0$0$0$0$0$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$1.0M$0$0$1.0M$1.0M$0$0$0$0
Other Assets$2.0M$0$0$0$0$0$0$0$0$0
Total Liabilities$1.0M$2.0M$11.0M$11.0M$9.0M$31.0M$13.0M$15.0M$11.0M$8.0M
Current Liabilities$1.0M$2.0M$5.0M$5.0M$6.0M$21.0M$11.0M$14.0M$11.0M$8.0M
Borrowings$0$0$3.0M$1.0M$3.0M$1.0M$4.0M$1.0M$1.0M$1.0M
Other Liabilities$1.0M$2.0M$8.0M$10.0M$6.0M$30.0M$9.0M$13.0M$9.0M$7.0M
Equity$0$0$0$1.0M$0$0$0$0$0$0
Reserves$5.0M$0$24.0M$18.0M$24.0M$19.0M$2.0M$-3.0M$12.0M$10.0M

For Allarity Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $15.0M; free cash flow was positive in 0 of 10 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-4.0M$-1.0M$-4.0M$-10.0M$-7.0M$-15.0M$-17.0M$-13.0M$-17.0M$-15.0M
Investing Cash Flow$0$0$2.0M$0$0$1.0M$1.0M$0$-1.0M$0
Financing Cash Flow$4.0M$1.0M$2.0M$-1.0M$0$1.0M$-1.0M$2.0M$-3.0M$-3.0M
Net Cash Flow$2.0M$-2.0M$0$1.0M$-1.0M$19.0M$-18.0M$-2.0M$19.0M$-5.0M
Free Cash Flow$-4.0M$-1.0M$-4.0M$-10.0M$-7.0M$-15.0M$-17.0M$-13.0M$-18.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-1.97
FCF Yield-83.29%
Quick Ratio1.11
Interest Coverage-10.15
Return 1Y16.83%
Return 3Y-99.93%
Return 5Y—

Allarity Therapeutics, Inc. (ALLR) financials — frequently asked questions

What is Allarity Therapeutics, Inc.'s annual revenue?

Allarity Therapeutics, Inc. (ALLR) reported annual revenue of $0 in its most recent fiscal year.

What is Allarity Therapeutics, Inc.'s net profit?

Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.0M in its most recent fiscal year.

What is ALLR EV/EBITDA?

Allarity Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.97. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
ALLR Overview ALLR Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.